Myocardial protection during ischemic cardiac arrest. The importance of magnesium in cardioplegic infusates.
The increasing use of coronary infusates for the protection of the human heart drug ischemic cardiac arrest has placed great emphasis on the need for a rational and safe formulation of any infusion solution. Using a rat heart model of cardiopulmonary bypass and ischemic cardiac arrest, we have found magnesium to be a highly effective component of protective infusates which can be additive to hypothermia and other protective agents. However, the concentration of magnesium bears a complex relationship to the degree of protection, a fact which stresses the need for the establishment of the correct concentration for optimal protection.
D000818:Animals; D001794:Blood Pressure; D001831:Body Temperature; D002712:Chlorides / Q000494:pharmacology; D003326:Coronary Circulation; D004305:Dose-Response Relationship, Drug; D006324:Heart Arrest, Induced / Q000379:methods*; D006339:Heart Rate; D007036:Hypothermia, Induced; D008278:Magnesium Sulfate / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D010477:Perfusion; D051381:Rats; D013997:Time Factors
D002712:Chlorides; D008278:Magnesium Sulfate